DiaMedica Therapeutics (DMAC) Return on Capital Employed Growth (3y) (2022 - 2026)

DiaMedica Therapeutics (DMAC) Return on Capital Employed Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -356.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -516.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -2,309.00
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 4,967.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -2,424.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - 513.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5,777.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 109.00
10 DiaMedica Therapeutics 360.22 Mn 360.22 Mn - -5,312.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -5,312.00
Mar 31, 2026 -1,716.00
Dec 31, 2025 -2,188.00
Sep 30, 2025 -4,992.00
Jun 30, 2025 -6,675.00
Mar 31, 2025 -4,474.00
Dec 31, 2024 -3,064.00
Sep 30, 2024 -421.00
Jun 30, 2024 2,256.00
Mar 31, 2024 1,178.00
Dec 31, 2023 607.00
Sep 30, 2023 2,121.00
Jun 30, 2023 4,673.00
Mar 31, 2023 4,396.00
Dec 31, 2022 9,109.00
Sep 30, 2022 6,586.00
Jun 30, 2022 3,939.00
Mar 31, 2022 10,816.00